Hospira Issues a Voluntary Nationwide Recall for Labetalol Hydrochloride Injection, USP, Due to the Potential of Cracked Glass
Date of publication: 13-04-2020
Hospira, Inc., a Pfizer company, is voluntarily recalling 3 lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial (NDC 0409-2267-20), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus® (NDC 0409-2267-25) to the hospital/institution level. Hospira, Inc. initiated this recall due to the discovery of cracks on the rim surface of vials for these lots, which is covered by the stopper and crimp seal. Źródło: http://www.fda.gov
